Cargando…
Severe acute respiratory syndrome coronavirus 2 seroprevalence and longitudinal antibody response following natural infection in pregnancy: A prospective cohort study
BACKGROUND: Antenatal care provides unique opportunities to assess severe acute respiratory syndrome coronavirus 2 seroprevalence and antibody response duration after natural infection detected during pregnancy; transplacental antibody transfer may inform peripartum and neonatal protection. We estim...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10467162/ https://www.ncbi.nlm.nih.gov/pubmed/37615311 http://dx.doi.org/10.1177/17455057231190955 |
_version_ | 1785099053606895616 |
---|---|
author | Drake, Alison L Escudero, Jaclyn N Aurelio, Morgan C Wetzler, Erica A Ellington, Sascha R Zapata, Lauren B Galang, Romeo R Snead, Margaret C Yamamoto, Krissy Salerno, Carol C Richardson, Barbra A Greninger, Alexander L Kachikis, Alisa B Englund, Janet A LaCourse, Sylvia M |
author_facet | Drake, Alison L Escudero, Jaclyn N Aurelio, Morgan C Wetzler, Erica A Ellington, Sascha R Zapata, Lauren B Galang, Romeo R Snead, Margaret C Yamamoto, Krissy Salerno, Carol C Richardson, Barbra A Greninger, Alexander L Kachikis, Alisa B Englund, Janet A LaCourse, Sylvia M |
author_sort | Drake, Alison L |
collection | PubMed |
description | BACKGROUND: Antenatal care provides unique opportunities to assess severe acute respiratory syndrome coronavirus 2 seroprevalence and antibody response duration after natural infection detected during pregnancy; transplacental antibody transfer may inform peripartum and neonatal protection. We estimated seroprevalence and durability of antibodies from natural infection (anti-nucleocapsid immunoglobulin G) among pregnant people, and evaluated transplacental transfer efficiency. OBJECTIVE AND DESIGN: We conducted a cross-sectional study to measure severe acute respiratory syndrome coronavirus 2 seroprevalence, and a prospective cohort study to longitudinally measure anti-nucleocapsid immunoglobulin G responses and transplacental transfer of maternally derived anti-nucleocapsid antibodies. METHODS: We screened pregnant people for the seroprevalence study between 9 December 2020 and 19 June 2021 for anti-nucleocapsid immunoglobulin G in Seattle, Washington. We enrolled anti-nucleocapsid immunoglobulin G positive people from the seroprevalence study or identified through medical records with positive reverse transcription polymerase chain reaction or antigen positive results in a prospective cohort between 9 December 2020 and 9 August 2022. RESULTS: In the cross-sectional study (N = 1284), 5% (N = 65) tested severe acute respiratory syndrome coronavirus 2 anti-nucleocapsid immunoglobulin G positive, including 39 (60%) without prior positive reverse transcription polymerase chain reaction results and 42 (65%) without symptoms. In the prospective cohort study (N = 107 total; N = 65 from the seroprevalence study), 86 (N = 80%) had anti-nucleocapsid immunoglobulin G positive results during pregnancy. Among 63 participants with delivery samples and prior anti-nucleocapsid positive results, 29 (46%) were anti-nucleocapsid immunoglobulin G negative by delivery. Of 34 remaining anti-nucleocapsid immunoglobulin G positive at delivery with paired cord blood, 19 (56%) had efficient transplacental anti-nucleocapsid immunoglobulin G antibody transfer. Median time from first anti-nucleocapsid immunoglobulin G positive to below positive antibody threshold was 19 weeks and did not differ by prior positive reverse transcription polymerase chain reaction status. CONCLUSIONS: Maternally derived severe acute respiratory syndrome coronavirus 2 antibodies to natural infection may wane before delivery. Vaccines are recommended for pregnant persons to reduce severe illness and confer protection to infants. |
format | Online Article Text |
id | pubmed-10467162 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-104671622023-08-31 Severe acute respiratory syndrome coronavirus 2 seroprevalence and longitudinal antibody response following natural infection in pregnancy: A prospective cohort study Drake, Alison L Escudero, Jaclyn N Aurelio, Morgan C Wetzler, Erica A Ellington, Sascha R Zapata, Lauren B Galang, Romeo R Snead, Margaret C Yamamoto, Krissy Salerno, Carol C Richardson, Barbra A Greninger, Alexander L Kachikis, Alisa B Englund, Janet A LaCourse, Sylvia M Womens Health (Lond) Original Research Article BACKGROUND: Antenatal care provides unique opportunities to assess severe acute respiratory syndrome coronavirus 2 seroprevalence and antibody response duration after natural infection detected during pregnancy; transplacental antibody transfer may inform peripartum and neonatal protection. We estimated seroprevalence and durability of antibodies from natural infection (anti-nucleocapsid immunoglobulin G) among pregnant people, and evaluated transplacental transfer efficiency. OBJECTIVE AND DESIGN: We conducted a cross-sectional study to measure severe acute respiratory syndrome coronavirus 2 seroprevalence, and a prospective cohort study to longitudinally measure anti-nucleocapsid immunoglobulin G responses and transplacental transfer of maternally derived anti-nucleocapsid antibodies. METHODS: We screened pregnant people for the seroprevalence study between 9 December 2020 and 19 June 2021 for anti-nucleocapsid immunoglobulin G in Seattle, Washington. We enrolled anti-nucleocapsid immunoglobulin G positive people from the seroprevalence study or identified through medical records with positive reverse transcription polymerase chain reaction or antigen positive results in a prospective cohort between 9 December 2020 and 9 August 2022. RESULTS: In the cross-sectional study (N = 1284), 5% (N = 65) tested severe acute respiratory syndrome coronavirus 2 anti-nucleocapsid immunoglobulin G positive, including 39 (60%) without prior positive reverse transcription polymerase chain reaction results and 42 (65%) without symptoms. In the prospective cohort study (N = 107 total; N = 65 from the seroprevalence study), 86 (N = 80%) had anti-nucleocapsid immunoglobulin G positive results during pregnancy. Among 63 participants with delivery samples and prior anti-nucleocapsid positive results, 29 (46%) were anti-nucleocapsid immunoglobulin G negative by delivery. Of 34 remaining anti-nucleocapsid immunoglobulin G positive at delivery with paired cord blood, 19 (56%) had efficient transplacental anti-nucleocapsid immunoglobulin G antibody transfer. Median time from first anti-nucleocapsid immunoglobulin G positive to below positive antibody threshold was 19 weeks and did not differ by prior positive reverse transcription polymerase chain reaction status. CONCLUSIONS: Maternally derived severe acute respiratory syndrome coronavirus 2 antibodies to natural infection may wane before delivery. Vaccines are recommended for pregnant persons to reduce severe illness and confer protection to infants. SAGE Publications 2023-08-24 /pmc/articles/PMC10467162/ /pubmed/37615311 http://dx.doi.org/10.1177/17455057231190955 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Research Article Drake, Alison L Escudero, Jaclyn N Aurelio, Morgan C Wetzler, Erica A Ellington, Sascha R Zapata, Lauren B Galang, Romeo R Snead, Margaret C Yamamoto, Krissy Salerno, Carol C Richardson, Barbra A Greninger, Alexander L Kachikis, Alisa B Englund, Janet A LaCourse, Sylvia M Severe acute respiratory syndrome coronavirus 2 seroprevalence and longitudinal antibody response following natural infection in pregnancy: A prospective cohort study |
title | Severe acute respiratory syndrome coronavirus 2 seroprevalence and longitudinal antibody response following natural infection in pregnancy: A prospective cohort study |
title_full | Severe acute respiratory syndrome coronavirus 2 seroprevalence and longitudinal antibody response following natural infection in pregnancy: A prospective cohort study |
title_fullStr | Severe acute respiratory syndrome coronavirus 2 seroprevalence and longitudinal antibody response following natural infection in pregnancy: A prospective cohort study |
title_full_unstemmed | Severe acute respiratory syndrome coronavirus 2 seroprevalence and longitudinal antibody response following natural infection in pregnancy: A prospective cohort study |
title_short | Severe acute respiratory syndrome coronavirus 2 seroprevalence and longitudinal antibody response following natural infection in pregnancy: A prospective cohort study |
title_sort | severe acute respiratory syndrome coronavirus 2 seroprevalence and longitudinal antibody response following natural infection in pregnancy: a prospective cohort study |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10467162/ https://www.ncbi.nlm.nih.gov/pubmed/37615311 http://dx.doi.org/10.1177/17455057231190955 |
work_keys_str_mv | AT drakealisonl severeacuterespiratorysyndromecoronavirus2seroprevalenceandlongitudinalantibodyresponsefollowingnaturalinfectioninpregnancyaprospectivecohortstudy AT escuderojaclynn severeacuterespiratorysyndromecoronavirus2seroprevalenceandlongitudinalantibodyresponsefollowingnaturalinfectioninpregnancyaprospectivecohortstudy AT aureliomorganc severeacuterespiratorysyndromecoronavirus2seroprevalenceandlongitudinalantibodyresponsefollowingnaturalinfectioninpregnancyaprospectivecohortstudy AT wetzlerericaa severeacuterespiratorysyndromecoronavirus2seroprevalenceandlongitudinalantibodyresponsefollowingnaturalinfectioninpregnancyaprospectivecohortstudy AT ellingtonsaschar severeacuterespiratorysyndromecoronavirus2seroprevalenceandlongitudinalantibodyresponsefollowingnaturalinfectioninpregnancyaprospectivecohortstudy AT zapatalaurenb severeacuterespiratorysyndromecoronavirus2seroprevalenceandlongitudinalantibodyresponsefollowingnaturalinfectioninpregnancyaprospectivecohortstudy AT galangromeor severeacuterespiratorysyndromecoronavirus2seroprevalenceandlongitudinalantibodyresponsefollowingnaturalinfectioninpregnancyaprospectivecohortstudy AT sneadmargaretc severeacuterespiratorysyndromecoronavirus2seroprevalenceandlongitudinalantibodyresponsefollowingnaturalinfectioninpregnancyaprospectivecohortstudy AT yamamotokrissy severeacuterespiratorysyndromecoronavirus2seroprevalenceandlongitudinalantibodyresponsefollowingnaturalinfectioninpregnancyaprospectivecohortstudy AT salernocarolc severeacuterespiratorysyndromecoronavirus2seroprevalenceandlongitudinalantibodyresponsefollowingnaturalinfectioninpregnancyaprospectivecohortstudy AT richardsonbarbraa severeacuterespiratorysyndromecoronavirus2seroprevalenceandlongitudinalantibodyresponsefollowingnaturalinfectioninpregnancyaprospectivecohortstudy AT greningeralexanderl severeacuterespiratorysyndromecoronavirus2seroprevalenceandlongitudinalantibodyresponsefollowingnaturalinfectioninpregnancyaprospectivecohortstudy AT kachikisalisab severeacuterespiratorysyndromecoronavirus2seroprevalenceandlongitudinalantibodyresponsefollowingnaturalinfectioninpregnancyaprospectivecohortstudy AT englundjaneta severeacuterespiratorysyndromecoronavirus2seroprevalenceandlongitudinalantibodyresponsefollowingnaturalinfectioninpregnancyaprospectivecohortstudy AT lacoursesylviam severeacuterespiratorysyndromecoronavirus2seroprevalenceandlongitudinalantibodyresponsefollowingnaturalinfectioninpregnancyaprospectivecohortstudy |